-
Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-04 Sven L. Van Laer, Pieterjan Van Rijckeghem, Vincent F. M. Segers
This case report describes a diagnosis of left ventricular anterior free-wall rupture in a patient given anticoagulant treatment for subacute myocardial infarction.
-
Addressing Evidence Gaps in Coronary Revascularization Trials. JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-04 Gregg W Stone,Clyde W Yancy,Mario Gaudino
-
Genome-Wide Association Study of Accessory Atrioventricular Pathways. JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-04 Hildur M Aegisdottir,Laura Andreasen,Rosa B Thorolfsdottir,Gardar Sveinbjornsson,Andrea B Jonsdottir,Lilja Stefansdottir,Gudmar Thorleifsson,Asgeir Sigurdsson,Gisli H Halldorsson,Julien Barc,Floriane Simonet,Vinicius Tragante,Asmundur Oddsson,Egil Ferkingstad,Jesper Hastrup Svendsen,Jonas Ghouse,Gustav Ahlberg,Christian Paludan-Müller,Katra Hadji-Turdeghal,Mariana Bustamante,Magnus O Ulfarsson,Anna
Importance Understanding of the genetics of accessory atrioventricular pathways (APs) and affiliated arrhythmias is limited. Objective To investigate the genetics of APs and affiliated arrhythmias. Design, Setting, and Participants This was a genome-wide association study (GWAS) of APs, defined by International Classification of Diseases (ICD) codes and/or confirmed by electrophysiology (EP) study
-
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-04 Matthew M Y Lee,Ahmad Masri,Michael E Nassif,Roberto Barriales-Villa,Theodore P Abraham,Brian L Claggett,Caroline J Coats,Juan Ramón Gimeno,Ian J Kulac,Isabela Landsteiner,Changsheng Ma,Martin S Maron,Iacopo Olivotto,Anjali T Owens,Scott D Solomon,Josef Veselka,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Fady I Malik,Lisa Meng,Amy Wohltman,Gregory D Lewis,
Importance Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) is a pivotal study characterizing the treatment effect of aficamten, a next-in-class cardiac myosin inhibitor, on a comprehensive set of exercise
-
What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques. JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-02 Steven E Nissen
-
Echoes of Concern—AI and Moral Agency in Medicine JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-02 Sarah C. Hull, Joseph J. Fins
This essay describes concerns that use of artificial intelligence (AI) as a replacement rather than a supplement in the provision of medical care may lead to loss of the art of medicine and the collaborative partnership between physician and patient.
-
Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-02 Flavio G. Biccirè, Ryota Kakizaki, Konstantinos C. Koskinas, Yasushi Ueki, Jonas Häner, Hiroki Shibutani, Jacob Lønborg, Ernest Spitzer, Juan F. Iglesias, Tatsuhiko Otsuka, George C. M. Siontis, Stefan Stortecky, Christoph Kaiser, Maria Ambühl, Laura Morf, Anna S. Ondracek, Robert-Jan van Geuns, David Spirk, Joost Daemen, François Mach, Stephan Windecker, Thomas Engstrøm, Irene Lang, Sylvain Losdat
ImportancePrevious studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach).ObjectiveTo investigate the effects of lipid-lowering therapy on coronary lesions with advanced atherosclerotic plaque features and presumably higher risk for future events.Design, Setting, and ParticipantsThe
-
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-30 Henri Lu, Brian L. Claggett, Milton Packer, Carolyn S. P. Lam, Karl Swedberg, Jean Rouleau, Michael R. Zile, Martin Lefkowitz, Akshay S. Desai, Pardeep Jhund, John J. V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
ImportanceSacubitril/valsartan is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalizations in patients with chronic HF. However, many of these patients are older and have multiple comorbidities that increase the risk of hospitalization for causes other than HF.ObjectiveTo assess the effects of sacubitril/valsartan on hospitalizations of any cause across the spectrum
-
Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-30 Jasmine Melissa Madsen, Thomas Engstrøm, Laust Emil Roelsgaard Obling, Yan Zhou, Lars Nepper-Christensen, Rasmus Paulin Beske, Niels Grove Vejlstrup, Lia Evi Bang, Christian Hassager, Fredrik Folke, Kasper Kyhl, Lars Bredevang Andersen, Helle Collatz Christensen, Laura Rytoft, Ketina Arslani, Lene Holmvang, Frants Pedersen, Ole Ahlehoff, Reza Jabbari, Charlotte Barfod, Mikkel Hougaard, Mikko Minkkinen
ImportanceIn patients with ST-segment elevation myocardial infarction (STEMI), acute inflammation is related to the extent of myocardial damage and may increase infarct size. Thus, administration of pulse-dose glucocorticoid in the very early phase of infarction may reduce infarct size.ObjectiveTo determine the cardioprotective effect of prehospital pulse-dose glucocorticoid in patients with STEMI
-
Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-28 Jessica A Regan,Marianna Fontana,Senthil Selvaraj
-
Comment on Risk of Cardiac Arrhythmias Among Climbers on Mount Everest. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-28 Stefano Savonitto,Patrizio Sarto
-
Comment on Risk of Cardiac Arrhythmias Among Climbers on Mount Everest-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-28 Thomas Pilgrim,Martina Rothenbühler,Kunjang Sherpa
-
Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-28 Nay Aung, Hannah L. Nicholls, C. Anwar A. Chahal, Mohammed Y. Khanji, Elisa Rauseo, Sucharitha Chadalavada, Steffen E. Petersen, Patricia B. Munroe, Perry M. Elliott, Luis R. Lopes
ImportanceThe population prevalence of cardiac transthyretin amyloidosis (ATTR) caused by pathogenic variation in the TTR gene (vATTR) is unknown.ObjectiveTo estimate the population prevalence of disease-causing TTR variants and evaluate associated phenotypes and outcomes.Design, Setting, and ParticipantsThis population-based cohort study analyzed UK Biobank (UKB) participants with whole-exome sequencing
-
Reporting Primary Language in Cardiology Clinical Trials JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-21 Zara Latif, Vanessa Blumer, Ersilia M. DeFilippis
This Viewpoint highlights the limited representation of patients with non-English language preference (NELP) in cardiology clinical trials and registries and recommends several methods to better include patients with NELP.
-
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-21 Aldostefano Porcari, Ambra Masi, Ana Martinez-Naharro, Yousuf Razvi, Rishi Patel, Adam Ioannou, Muhammad U. Rauf, Giulio Sinigiani, Brendan Wisniowski, Stefano Filisetti, Jasmine Currie-Cathey, Sophie O’Beara, Tushar Kotecha, Dan Knight, James C. Moon, Gianfranco Sinagra, Ruta Virsinskaite, Janet Gilbertson, Lucia Venneri, Aviva Petrie, Helen Lachmann, Carol Whelan, Peter Kellman, Sriram Ravichandran
ImportanceCardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless of the extent of cardiac amyloid infiltration.ObjectiveTo assess the differences between serum biomarkers, echocardiography, and cardiovascular magnetic resonance (CMR)
-
Tombstone Pattern Electrocardiogram in a Young Woman JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-21 Yun Chen, Ping Ge, Xiao-Feng Zhuang
A woman in her mid-20s presented with acute fever, chest pain, and exertional dyspnea. Electrocardiogram results showed sinus tachycardia, QRS widening, low-voltage complexes, and ST-segment elevation. What would you do next?
-
Epicardial and Pericardial Fat-Separated But Under the Same Roof-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-14 Joel T Rämö,Patrick T Ellinor,James P Pirruccello
-
Epicardial and Pericardial Fat-Separated But Under the Same Roof. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-14 Gianluca Iacobellis
-
Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-14 Pieter A. Vriesendorp, Shane Nanayakkara, Samuel Heuts, Jocasta Ball, Jaya Chandrasekar, Ronald Dick, Kawa Haji, Nay Min Htun, David McGaw, Samer Noaman, Sonny Palmer, Sesto Cairo, Mark Shulman, Enjarn Lin, Stuart Hastings, Benedict Waldron, George Proimos, Kean H. Soon, Matias B. Yudi, Adam Zimmet, Dion Stub, Antony S. Walton
ImportanceVascular complications after transfemoral transcatheter aortic valve implantation (TAVI) remain an important cause of procedure-related morbidity. Routine reversal of anticoagulation with protamine at the conclusion of transfemoral TAVI could reduce complications, but data remain scarce.ObjectiveTo evaluate the efficacy and safety of routine protamine administration after transfemoral TAVI
-
Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-14 Dalane W. Kitzman, Adriaan A. Voors, Robert J. Mentz, Gregory D. Lewis, Shira Perl, Robin Myte, Grace Kaguthi, C. David Sjöström, Christian Källgren, Sanjiv J. Shah
ImportanceElevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors’ knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.ObjectiveTo investigate the efficacy and safety of the novel urate transporter–1 inhibitor, verinurad,
-
Evaluating Pregnancy Safety During Cardiology Training. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-07 Leila Haghighat,Shadi Kalantarian,Jacqueline T DesJardin,Cara N Pellegrini
-
Changing the Frame of Post-AMI Left Ventricular Dysfunction: Sudden Cardiac Death, a Diminishing Complication. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-07 Gregg C Fonarow,Kristen K Patton,Clyde W Yancy
-
Progressive Cardiogenic Shock After Catheter Ablation in a Man Aged 78 Years. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-07 Karim Benali,Benjamin Seguy,Frederic Sacher
-
The Urgent Need to Improve Outcomes for Pregnant Cardiovascular Trainees. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-07 Ann Marie Navar,Sadiya S Khan,Kristen K Patton,Sharlene M Day,Roxana Mehran
-
Rethinking Anticoagulation for Left Atrial Appendage Closure. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-07 Vinay Guduguntla,Kristen K Patton
-
Rates of Sudden Death After Myocardial Infarction—Insights From the VALIANT and PARADISE-MI Trials JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-07 James P. Curtain, Marc A. Pfeffer, Eugene Braunwald, Brian L. Claggett, Christopher B. Granger, Lars Køber, Eldrin F. Lewis, Aldo P. Maggioni, Doug L. Mann, Jean L. Rouleau, Scott D. Solomon, Philippe Gabriel Steg, Peter V. Finn, Alberto Fernandez, Karola S. Jering, John J. V. McMurray
ImportanceSudden death is a leading cause of death after acute myocardial infarction (AMI). The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials enrolled patients with pulmonary congestion and/or left ventricular dysfunction after AMI. Whether the prognosis in such patients
-
Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-07 Xavier Freixa, Ignacio Cruz-González, Pedro Cepas-Guillén, Xavi Millán, Pablo Antúnez-Muiños, Eduardo Flores-Umanzor, Lluís Asmarats, Ander Regueiro, Sergio López-Tejero, Chi-Hion Pedro Li, Laura Sanchis, Josep Rodés-Cabau, Dabit Arzamendi
ImportanceOptimal antithrombotic therapy after percutaneous left atrial appendage occlusion (LAAO) is not well established as no randomized evaluation has been performed to date.ObjectiveTo compare the efficacy and safety of low-dose direct oral anticoagulation (low-dose DOAC) vs dual antiplatelet therapy (DAPT) for 3 months after LAAO.Design, Setting, and ParticipantsThe ADALA (Low-Dose Direct Oral
-
Postpartum Remote Blood Pressure Monitoring-When Control Is of the Essence. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-01 Sadiya S Khan
-
Reflections of an Editorial Fellow-A Window Into Medical Publishing. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-01 Vinay Guduguntla
-
Indigenous Representation and Belonging in Cardiology-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-01 Sarah C Snow,Brooke Alhanti,Pamela S Douglas
-
Indigenous Representation and Belonging in Cardiology. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-01 Jeffrey E Jones,Kekoa Taparra
-
Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-01 Oliver B Vad,Laia M Monfort,Christian Paludan-Müller,Konstantin Kahnert,Søren Z Diederichsen,Laura Andreasen,Luca A Lotta,Jonas B Nielsen,Alicia Lundby,Jesper H Svendsen,Morten S Olesen,
Importance Atrial fibrillation (AF) has a substantial genetic component. The importance of polygenic risk is well established, while the contribution of rare variants to disease risk warrants characterization in large cohorts. Objective To identify rare predicted loss-of-function (pLOF) variants associated with AF and elucidate their role in risk of AF, cardiomyopathy (CM), and heart failure (HF) in
-
RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-01 Keiko Hikino,Satoshi Koyama,Kaoru Ito,Yoshinao Koike,Masaru Koido,Takayoshi Matsumura,Ryo Kurosawa,Kohei Tomizuka,Shuji Ito,Xiaoxi Liu,Yuki Ishikawa,Yukihide Momozawa,Takayuki Morisaki,Yoichiro Kamatani,Taisei Mushiroda,Chikashi Terao,
Importance Vasospastic angina (VSA) is vasospasm of the coronary artery and is particularly prevalent in East Asian populations. However, the specific genetic architecture for VSA at genome-wide levels is not fully understood. Objective To identify genetic factors associated with VSA. Design, Setting, and Participants This was a case-control genome-wide association study of VSA. Data from Biobank Japan
-
Social Vulnerability and Poor Health Outcomes: There Is No Nadir. JAMA Cardiol. (IF 14.8) Pub Date : 2024-08-01 Clyde W Yancy,Sadiya S Khan
-
Acute Myocardial Infarction Admissions During the COVID-19 Peak. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-31 Vinay Guduguntla,Robert O Bonow,Clyde W Yancy
-
Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-31 Jagmeet P Singh,Christopher A Rinaldi,Prashanthan Sanders,Spencer H Kubo,Simon James,Imran K Niazi,Timothy Betts,Christian Butter,Toshimasa Okabe,Ryan Cunnane,Emad Aziz,Mauro Biffi,Amir Zaidi,Jeffrey Alison,Pascal Defaye,Angelo Aurrichio,Michael R Gold,JoAnn Lindenfeld,Tyson Rogers,Mary Norine Walsh,
Importance Approximately 40% of patients with heart failure (HF) who are eligible for cardiac resynchronization therapy (CRT) either fail to respond or are untreatable due to anatomical constraints. Objective To assess the safety and efficacy of a novel, leadless, left ventricular (LV) endocardial pacing system for patients at high risk for a CRT upgrade or whose coronary sinus (CS) lead placement/pacing
-
Factors Underlying Reduced Hospitalizations for Myocardial Infarction During the COVID-19 Pandemic JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-31 Andrew D. Wilcock, Jose R. Zubizarreta, Rishi K. Wadhera, Robert W. Yeh, Kori S. Zachrison, Lee H. Schwamm, Ateev Mehrotra
ImportanceThe incidence of hospital encounters for acute myocardial infarction (AMI) decreased sharply early in the COVID-19 pandemic and has not returned to prepandemic levels. There has been an ongoing debate about what mechanism may underlie this decline, including patients avoiding the hospital for treatment, excess mortality from COVID-19 among patients who would otherwise have had an AMI, a reduction
-
The Politics of HFpEF-What's Good for the Left Is Good for the Right. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-24 Gaurav Gulati,Sheldon E Litwin
-
Noninvasive Visualization of the Atrioventricular Conduction System Using Cardiac Computed Tomography JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-24 Mirmilad Khoshknab, Tarek Zghaib, Lingyu Xu, Timothy Markman, Constantine Mavroudis, Benoit Desjardins, Saman Nazarian
ImportanceNoninvasive localization of the compact atrioventricular node and the proximal specialized conduction system (AVCS) would enhance planning for transcatheter aortic valve and complex or congenital heart disease surgical procedures.ObjectiveTo test the hypothesis that preprocedure contrast-enhanced cardiac computed tomography (CECT) can accurately localize the AVCS by identification of the
-
Dapagliflozin and Right Ventricular–Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-24 Yogesh N. V. Reddy, Rickey E. Carter, Hidemi Sorimachi, Massar Omar, Dejana Popovic, Alessio Alogna, Michael D. Jensen, Barry A. Borlaug
ImportanceIncreases in pulmonary capillary wedge pressure (PCWP) during exercise reduce pulmonary artery (PA) compliance, increase pulsatile right ventricular (RV) afterload, and impair RV-PA coupling in patients with heart failure with preserved ejection fraction (HFpEF). The effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on pulmonary vascular properties and RV-PA coupling
-
Contribution of Clinical Trial Event Data by Data Source JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-24 Jennifer A. Rymer, Hillary Mulder, Lisa M. Wruck, Daniel Muñoz, Sunil Kripalani, Mark B. Effron, Kamal Gupta, Eileen Handberg, Sandeep Jain, Saket Girotra, Jeffrey Whittle, Rachel Hess, Catherine P. Benziger, Kirk U. Knowlton, Lesley H. Curtis, Matthew T. Roe, Bradley G. Hammill, Russell L. Rothman, Robert Harrington, Adrian Hernandez, W. Schuyler Jones
ImportancePragmatic randomized clinical trials (RCTs) often use multiple data sources to examine clinical events, but the relative contribution of data sources to clinical end-point rates is understudied.ObjectiveTo assess the contribution of data sources (electronic health records [EHRs], public/private insurance claims, and/or participant-reported data) to clinical end points among ADAPTABLE participants
-
Racial Disparities in Sports Cardiology: A Review. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-17 Sheela Krishnan,James Sawalla Guseh,Merije Chukumerije,Aubrey J Grant,Peter N Dean,Jeffrey J Hsu,Mustafa Husaini,Dermot M Phelan,Ankit B Shah,Katie Stewart,Meagan M Wasfy,Quinn Capers,Utibe R Essien,Amber E Johnson,Benjamin D Levine,Jonathan H Kim,
Importance Racial disparities in cardiovascular health, including sudden cardiac death (SCD), exist among both the general and athlete populations. Among competitive athletes, disparities in health outcomes potentially influenced by social determinants of health (SDOH) and structural racism remain inadequately understood. This narrative review centers on race in sports cardiology, addressing racial
-
Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-17 Benoit J. Arsenault, Krithika Loganath, Arnaud Girard, Simona Botezatu, Kang H. Zheng, Evangelos Tzolos, Kathia Abdoun, Lionel Tastet, Romain Capoulade, Nancy Côté, Neil Craig, Kwan L. Chan, James W. Tam, Koon K. Teo, Christian Couture, Marie-Annick Clavel, Patrick Mathieu, Sébastien Thériault, Erik S. G. Stroes, David E. Newby, Sotirios Tsimikas, Philippe Pibarot, Marc R. Dweck
ImportanceThere are currently no pharmacological treatments available to slow hemodynamic progression of aortic stenosis. Plasma lipoprotein(a) concentrations predict incident aortic stenosis but its association with hemodynamic progression is controversial.ObjectiveTo determine the association between plasma lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis
-
Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-17 Nick S. Nurmohamed, Emilie L. Gaillard, Shant Malkasian, Robin J. de Groot, Shirin Ibrahim, Michiel J. Bom, Yannick Kaiser, James P. Earls, James K. Min, Jeffrey Kroon, R. Nils Planken, Ibrahim Danad, Alexander R. van Rosendael, Andrew D. Choi, Erik S.G. Stroes, Paul Knaapen
ImportanceLipoprotein(a) (Lp[a]) is a causal risk factor for cardiovascular disease; however, long-term effects on coronary atherosclerotic plaque phenotype, high-risk plaque formation, and pericoronary adipose tissue inflammation remain unknown.ObjectiveTo investigate the association of Lp(a) levels with long-term coronary artery plaque progression, high-risk plaque, and pericoronary adipose tissue
-
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-10 André Zimerman, Eugene Braunwald, Jan Steffel, Nicolas M. Van Mieghem, Michael G. Palazzolo, Sabina A. Murphy, Cathy Zi Li Chen, Martin Unverdorben, Christian T. Ruff, Elliott M. Antman, Robert P. Giugliano
ImportanceIn older patients with atrial fibrillation who take anticoagulants for stroke prevention, bleeding is increased compared with younger patients, thus, clinicians frequently prescribe lower than recommended doses in older patients despite limited randomized data.ObjectiveTo evaluate ischemic and bleeding outcomes in patients 80 years and older with atrial fibrillation receiving edoxaban, 60
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-10 Catherine P. Benziger, Amanda Stebbins, Lisa M. Wruck, Mark B. Effron, Guillaume Marquis-Gravel, Peter M. Farrehi, Saket Girotra, Kamal Gupta, Sunil Kripalani, Daniel Munoz, Tamar S. Polonsky, Amber Sharlow, Jeffrey Whittle, Robert A. Harrington, Russell L. Rothman, Adrian F. Hernandez, W. Schuyler Jones
ImportanceAtherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dosed daily at 81 mg or 325 mg in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical
-
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-03 Eric Q Klug,Sara Llerena,Lesley J Burgess,Nyda Fourie,Russell Scott,Jeff Vest,Kate Caldwell,David Kallend,Evan A Stein,
Importance Recent changes in national and international lipid guidelines for reducing cardiovascular events recommend additional drugs, greater reductions, and lower targets for low-density lipoprotein cholesterol (LDL-C) if not attained with statins. The achievement of these targets with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has not yet been evaluated in a randomized clinical
-
Incidental Complication From a Left Atrial Appendage Device JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-03 Rimmy Garg, Sudhir Mungee, Rebecca Baumann
This case report describes a diagnosis of extracardiac mural thrombus and pulmonary emboli resulting from a left atrial appendage device in a patient with atrial fibrillation.
-
Large-Scale Proteomics in Early Pregnancy and Hypertensive Disorders of Pregnancy JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-03 Philip Greenland, Mark R. Segal, Rebecca B. McNeil, Corette B. Parker, Victoria L. Pemberton, William A. Grobman, Robert M. Silver, Hyagriv N. Simhan, George R. Saade, Peter Ganz, Priya Mehta, Janet M. Catov, C. Noel Bairey Merz, Jasmina Varagic, Sadiya S. Khan, Samuel Parry, Uma M. Reddy, Brian M. Mercer, Ronald J. Wapner, David M. Haas
ImportanceThere is no consensus regarding the best method for prediction of hypertensive disorders of pregnancy (HDP), including gestational hypertension and preeclampsia.ObjectiveTo determine predictive ability in early pregnancy of large-scale proteomics for prediction of HDP.Design, Setting, and ParticipantsThis was a nested case-control study, conducted in 2022 to 2023, using clinical data and
-
Rheumatic Heart Disease-A Neglected Tragedy in Young Patients. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-01 Kumar Narayanan,Eloi Marijon
-
Educational Attainment and Cardiovascular Risk-A Missed Opportunity?-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-01 Jared W Magnani,Norrina B Allen
-
Educational Attainment and Cardiovascular Risk-A Missed Opportunity? JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-01 Giovanni Veronesi,Frank Kee,Marco M Ferrario
-
Management Challenges for Bioprosthetic Aortic Valve Failure. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-01 Vinay Guduguntla,Robert O Bonow
-
Becoming a Co-Survivor-Reflections From the ICU. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-01 Courtney Julia Burns
-
Osteosarcopenia and Mortality After Transcatheter Aortic Valve Replacement. JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-01 Patrick T O'Gara,Vinay Guduguntla,Robert O Bonow
-
Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome JAMA Cardiol. (IF 14.8) Pub Date : 2024-06-26 Jinho Lee, Do-Yoon Kang, Hoyun Kim, Yeonwoo Choi, Sangyong Jo, Jung-Min Ahn, Seonok Kim, Yong-Hoon Yoon, Seung-Ho Hur, Cheol Hyun Lee, Won-Jang Kim, Se Hun Kang, Chul Soo Park, Bong-Ki Lee, Jung-Won Suh, Jae Woong Choi, Kee-Sik Kim, Su Nam Lee, Seung-Jung Park, Duk-Woo Park
ImportanceThe appropriate follow-up surveillance strategy for patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI) remains unknown.ObjectiveTo assess clinical outcomes in patients with and without ACS who have undergone high-risk PCI according to a follow-up strategy of routine stress testing at 12 months after PCI vs standard care alone.Design, Setting
-
Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension: A Randomized Clinical Trial. JAMA Cardiol. (IF 14.8) Pub Date : 2024-06-18 Xiaofan Guo,Nanxiang Ouyang,Guozhe Sun,Naijin Zhang,Zhao Li,Xingang Zhang,Guangxiao Li,Chang Wang,Lixia Qiao,Ying Zhou,Zihan Chen,Chuning Shi,Songyue Liu,Wei Miao,Danxi Geng,Pengyu Zhang,Yingxian Sun,
Importance The sustainable effectiveness and safety of a nonphysician community health care practitioner-led intensive blood pressure intervention on cardiovascular disease have not, to the authors' knowledge, been studied, especially in the older adult population. Objective To evaluate such a multifaceted model with a more stringent blood pressure treatment goal (<130/80 mm Hg) among patients aged
-
A Pathway to Better Blood Pressure Control. JAMA Cardiol. (IF 14.8) Pub Date : 2024-06-18 Daniel W Jones
-
Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non–HDL-C Levels JAMA Cardiol. (IF 14.8) Pub Date : 2024-06-12 Ahmed Sayed, Eric D. Peterson, Salim S. Virani, Allan D. Sniderman, Ann Marie Navar
ImportanceAlthough apolipoprotein B (apoB) is a superior marker of lipid-related risk compared with low-density lipoprotein cholesterol (LDL-C), few data exist to translate the goals and thresholds from LDL-C to their apoB equivalent. In addition, although current American College of Cardiology/American Heart Association guidelines provide a relative indication for apoB measurement among individuals
-
Postpartum Ambulatory Blood Pressure Patterns Following New-Onset Hypertensive Disorders of Pregnancy JAMA Cardiol. (IF 14.8) Pub Date : 2024-06-12 Alisse Hauspurg, Kripa Venkatakrishnan, Latima Collins, Malamo Countouris, Jacob Larkin, Beth Quinn, Nuzhat Kabir, Janet Catov, Lara Lemon, Hyagriv Simhan
ImportanceAfter a hypertensive disorder of pregnancy, hypertension can worsen in the postpartum period following hospital discharge. Risk factors for ongoing hypertension and associated outcomes have not been well characterized.ObjectiveTo identify risk factors and characterize outcomes for individuals with ongoing hypertension and severe hypertension following hospital discharge post partum through